Back to Journals » Infection and Drug Resistance » Volume 13

ACEIs and ARBs and Their Correlation with COVID-19: A Review

Authors Yehualashet AS, Belachew TF

Received 28 May 2020

Accepted for publication 7 August 2020

Published 16 September 2020 Volume 2020:13 Pages 3217—3224


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Suresh Antony

Awgichew Shewasinad Yehualashet,1 Teshome Fentik Belachew2

1Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia; 2Department of Pharmacy, Debre Birhan Health Science College, Debre Birhan, Ethiopia

Correspondence: Awgichew Shewasinad Yehualashet Pharmacology and Toxicology Unit, Department of Pharmacy
College of Health Sciences, Debre Berhan University, PO BOX. 445, Debre Berhan, Ethiopia
Tel +251 935450290
Email [email protected]

Abstract: Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.

Keywords: coronavirus, COVID-19, ACEIs, ARBs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]